Latest Intelligence on Oncology in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Type Product title / description Pub Price
Expert View
Expert View

Adult acute leukemia: demand for innovative drugs that prolong survival

A new report estimates that there will be approximately 84,000 cases of adult and childhood leukemia in the world's seven major pharmaceutical markets in 2006. Acute leukemias will account for 43% of these cases, and, although this market is relatively small compared to other cancer types, the clear unmet needs and regulatory incentives should help encourage drug makers.

Published By Datamonitor
11 May 2006
CommentWire
CommentWire

Amgen: denosumab deal maximizes potential in tough European market

Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.

Published By Datamonitor
29 Jul 2009
Expert View
Expert View

ASCO 2010: first-line chronic myeloid leukemia becomes next battleground for Sprycel and Tasigna

Datamonitor attended this year's meeting of the American Society of Clinical Oncology, where Bristol-Myers Squibb and Novartis revealed that their respective second-generation kinase inhibitors both surpass current standard of care Gleevec in first-line chronic myeloid leukemia. With little differentiating the two agents, a fierce marketing war will determine which becomes the new market leader.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

ASCO 2010: ipilimumab achieves breakthrough in 'long dark tunnel' of metastatic melanoma

At this year's American Society of Clinical Oncology meeting, Bristol-Myers Squibb presented data for its monoclonal antibody ipilimumab in metastatic melanoma. Research and development in this area has been underwhelming over the past few years and, despite its high rate of adverse events, ipilimumab represents a breakthrough in the treatment of metastatic melanoma.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

ASCO meeting 2009: current blockbusters advance standard care in new indications

Datamonitor attended the American Society of Clinical Oncology's 45th Annual Meeting in Orlando, Florida, to assess the key highlights of the conference. A number of promising presentations evaluated the potential of currently marketed agents to successfully combine with conventional chemotherapy in indications with persistent high unmet needs.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

ASCO meeting 2009: is maintenance the new paradigm for the treatment of NSCLC?

The numerous studies of maintenance therapy which were presented at this year's American Society of Clinical Oncology meeting suggest that pharmaceutical groups are looking to tap into a new treatment setting in NSCLC. However, maintenance therapy is unlikely to become a new paradigm unless biomarker-driven studies help identify the patients which derive the greatest benefit from this treatment.

Published By Datamonitor
11 Jun 2009
Expert View
Expert View

ASH 2009: competition between Velcade and Revlimid intensifies in multiple myeloma

Datamonitor attended this year's American Society of Hematology annual meeting in New Orleans, focusing on key developments in hematological malignancies. While recent trial results are likely to support new applications for Velcade and Revlimid in first-line multiple myeloma, the data also suggest that the future of treatment may actually be a combination of the two.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML

At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely that the drug will achieve the same market penetration as Gleevec in newly diagnosed patients due to fierce competition from Sprycel.

Published By Datamonitor
11 Dec 2009
CommentWire
CommentWire

AstraZeneca: Zactima development continues apace in lung cancer

The continuing development of Zactima in non-small-cell lung cancer will be welcome news for AstraZeneca, following the recent failure of Recentin in the same indication. Success in this indication now hinges on whether Zactima's mechanism of action can translate into notable clinical benefit.

Published By Datamonitor
14 Mar 2008
Expert View
Expert View

AUA 2010: vaccine data and potential new treatments drive interest in prostate cancer

This year's meeting of the American Urological Association saw several major pharmaceutical players presenting new data and discussing potential new pathways for disease treatment. Among the areas of focus was prostate cancer, with Dendreon presenting new data for its groundbreaking vaccine Provenge and Amgen highlighting the potential of Prolia in the treatment of this disease.

Published By Datamonitor
04 Jun 2010

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.